MAPK8 and diffuse large B-cell lymphoma: Preclinical studies in DLBCL and MM indicate that obatoclax/bortezomib- or obatoclax/carfilzomib- as well as ricolinostat/carfilzomib mediated lethality in DLBCL cells in vitro and in vivo includes activation of the stress-related JNK1 signaling pathway [371, 560–562].